Clinical trials: Empagliflozin
Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
To rule out the beneficial effect of SGLT2-I to reduce liver fat, and change in inflammatory markers (ALT, AST) in type 2 diabetic patients with non-alcoholic fatty liver disease.
- Trial name
- NCT06668753
- Testing
- Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab
- Volunteers
- 114 people
- Sponsor
- Assiut University
Chronic Kidney Disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.
- Trial name
- NCT07107945
- Testing
- Empagliflozin
- Where
- 93 sites in United States, Argentina and 16 more
- Volunteers
- 135 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Metabolic Surgery for Atrial Fibrillation Elimination
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030.
- Trial name
- METSAFE (NCT07027969)
- Testing
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ali Aminian
Type 2 Diabetes
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
In normal physiology, glucagon from pancreatic alpha cells plays an important role in maintaining glucose homeostasis via its regulatory effect on hepatic glucose production.
- Trial name
- NCT02792400
- Testing
- LY2403021, Standardised liquid meal, Linagliptin
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Type 2
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
To compare the risk of acute pancreatitis in patients with Type 2 diabetes mellitus (T2DM) newly initiating empagliflozin to that of patients newly initiating other oral non-incretin/non-Sodium glucose co-transporter-2 inhibitor…
- Trial name
- NCT05162014
- Testing
- empagliflozin, Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
- Where
- Germany
- Volunteers
- 494,679 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients…
- Trial name
- NCT06149793
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Autosomal Dominant Polycystic Kidney
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
- Trial name
- EMPA-PKD (NCT06391450)
- Testing
- Empagliflozin 10 MG
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Hannover Medical School
Acute Myocardial Infarction (AMI), Type 2 Diabetes Mellitus (T2DM)
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- SGLT2i-AMI (NCT07198191)
- Testing
- SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), DPP4 inhibitors
- Where
- South Korea
- Volunteers
- 200,000 people
- Sponsor
- Yonsei University
Diabetic Nephropathies
Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease
The prevalence of diabetes mellitus is increasing worldwide, and its complications are one of the leading causes of mortality from non-communicable diseases.
- Trial name
- NCT05638880
- Testing
- Valsartan 80 mg, Empagliflozin 10 MG, Levocetirizine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mostafa Bahaa
Dumping Syndrome, Hypoglycemia, Reactive
Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass
Bariatric surgery is an effective anti-obesity treatment providing durable weight loss and profound beneficial effects on glucose metabolism.
- Trial name
- NCT05057819
- Testing
- Empagliflozin 25 MG
- Where
- Switzerland
- Volunteers
- 22 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Type 2 Diabetes
Impact of Empaglifozine on Cardiac Ectopic Fat
There is substantial evidence supporting the fact that ectopic fat accumulation is an important contributor to type 2 diabetes complications and cardiovascular risk [1].
- Trial name
- EMPACEF (NCT03118336)
- Testing
- Empagliflozin 10Mg Tab
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
Evaluation of clinical outcomes (specifically cardiovascular outcomes like hospitalization for heart failure), and healthcare cost, and resource utilization, among patients on empagliflozin as an add-on therapy to metformin…
- Trial name
- NCT05102071
- Testing
- empagliflozin, metformin, sulfonylurea
- Where
- United States
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
The objectives of this study are to monitor the safety and effectiveness of Esgliteo in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting.
- Trial name
- NCT05130463
- Testing
- Empagliflozin/Linagliptin
- Where
- 30 sites in South Korea
- Volunteers
- 1,053 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Coronary Heart Disease
Effect of Empagliflozin on Ventricular Repolarization.
The present project aims to investigate if the empagliflozin has an antiarrhythmic action. Analyzing the T-wave heterogeneity index, a new electrocardiographic risk marker associated with the prediction of cardiovascular risk, in…
- Conditions
- Diabetes Mellitus, Type 2, Coronary Heart Disease, Arrythmia, Cardiac
- Trial name
- EMPATHYHEART (NCT04117763)
- Testing
- Empagliflozin 25 MG
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- University of Sao Paulo
Diabetes Mellitus, Type 2
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.
- Trial name
- NCT02121483
- Testing
- empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 27 people
- Sponsor
- Boehringer Ingelheim
Cardiovascular Diseases, Left Ventricular Hypertrophy
Empagliflozin and Cardiac Remodelling in People Without Diabetes
The purpose of this study is to evaluate the effects of empagliflozin on cardiac structure, function and circulating biomarkers in patients with cardiovascular risk factors, but without diabetes.
- Trial name
- EMPA-HEART 2 (NCT04461041)
- Testing
- Empagliflozin
- Where
- 4 sites in Canada, Taiwan
- Volunteers
- 169 people
- Sponsor
- Unity Health Toronto
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
The Effect of Empagliflozin on Glucose Metabolism, Weight, Blood Pressure and Cardiac Function (NT-proBNP) Should be Investigated
In summary, the registry should provide novel insight into potential mechanisms of cardiovascular risk reduction in patients treated with Empagliflozin with an indication of intensified glucose lowering therapy based on their…
- Trial name
- Empa (NCT03131232)
- Volunteers
- 46 people
- Sponsor
- RWTH Aachen University
Non Alcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
Fatty liver disease is an increasingly recognized health problem in patients with type 2 diabetes mellitus (T2DM). Sodium glucose co-transporter type 2 (SGLT-2) inhibitors are a new class of anti-diabetic agents that cause weight…
- Trial name
- E-LIFT (NCT02686476)
- Testing
- Empagliflozin
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
End Stage Renal Disease on Dialysis
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis.
- Trial name
- EMPA-PD (NCT05671991)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Yale University